In drug development, researchers are investigating the viability of synthetic data as an alternative to RWD in some of its AI-informed approaches. Let’s take a closer look at how the use of synthetic data is impacting the drug development landscape.
In drug development, researchers are investigating the viability of synthetic data as an alternative to RWD in some of its AI-informed approaches. Let’s take a closer look at how the use of synthetic data is impacting the drug development landscape.
In this blog, we take a look at some specific ways current and emerging AI technologies are poised to improve clinical trials – from processes to patient outcomes – and what to look for when choosing an AI partner or platform.
In this blog, we take a look at some specific ways current and emerging AI technologies are poised to improve clinical trials – from processes to patient outcomes – and what to look for when choosing an AI partner or platform.
Researchers are beginning to look at the utility of generative AI in drug development for specific ways this particular type of machine learning technology might help streamline, improve, or otherwise accelerate the development of new drugs. Here’s what you need to know about generative AI and drug development.
Researchers are beginning to look at the utility of generative AI in drug development for specific ways this particular type of machine learning technology might help streamline, improve, or otherwise accelerate the development of new drugs. Here’s what you need to know about generative AI and drug development.
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.